Disclosures: Tomoaki Kato – Grant/Research Support: Novartis The following people have nothing to disclose: Andrew Wehrman, Nadia Ovchinsky, Adam Griesemer, Steven J. Lobritto, Mercedes Martinez, Jean C. Emond Background The role

of the PET-CT for clinical staging of HCC, patient selection for liver transplantation, recurrence and prediction of survival is controversial. Aim To evaluate the relation between FDG positivity and recurrence, survival check details and histopathology in living donor liver transplantation. Methods All patients with HCC who underwent living donor liver transplantation (LDLT) between June 2011 and December 2013 were retrospectively analyzed. Imaging data, differantiation, AFP, number of tumors and size, recurrence and survival were reported and correlated to FDG-PET CT scanning. Results There were

62 patients, in a mean age of 54 years and the mean follow-up of all patients was 20.4±11.9 months. The comparison of the results between PET-CT negative and positive patients have shown that the maximum tumor size was larger in PET-CT positive vs negatives (p= 0.04), PET-positive patients had higher mortality and recurrence rates than PET-CT negative patients (p<0.05), figure 1. One-year survival was significantly lower in PET-CT positive patients vs negatives (82% vs 100%, p=0.04), figure 1. However, there were no differences according to AFP, grade and microvasculare invasion (p>0.05). Conclusion The present study has shown that pre-transplant PET-CT positivity is a marker of poor prognosis of HCC and shows lower survival and higher tumor HSP inhibitor recurrence rates after LDLT. However, especially in pre-transplant setting, its role should be studied with higher 上海皓元医药股份有限公司 number of patients. Disclosures:

The following people have nothing to disclose: Murat Akyildiz, Arzu Oezcelik, Gokhan Gungor, Nergis Ekmen, Necdet Guler, Onur Yaprak, Yalcin Erdogan, Gulen B. Dogusoy, Murat Dayangac, Yildiray Yuzer, Yaman Tokat Background: Gilbert’s syndrome is a benign inherited status, which is characterized by mild unconjugated hyperbilirubinemia episodes in absence of haemolysis or liver disease. The data in the literature is very limited to answer the question whether is it safe to accept donors with Gilbert’s syndrome for living donor liver transplantation or not. Aim: The aim of our study was to evaluate the safety of donors with Gilbert’s syndrome and to compare the outcome of their recipience with recipience of none-Gilbert’s donors. Methods: Between 2004 and May 2014, 600 living donor liver transplantation were performed in our center. The pre-, intra- and postoperative data of these patients and theirs donors were retrospectively analyzed. Donors with serum bilirubin level greater than 1,2 mg/dL (20,5 ^mol/L) were identified as a Gilbert’s syndrome.